Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Bayer
Compass Therapeutics
Pliant Therapeutics, Inc.
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Travera Inc
University Health Network, Toronto
Alliance for Clinical Trials in Oncology
National Institutes of Health Clinical Center (CC)
Wake Forest University Health Sciences
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
NRG Oncology
Institut Cancerologie de l'Ouest
Memorial Sloan Kettering Cancer Center
Sotio Biotech Inc.
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Brigham and Women's Hospital
M.D. Anderson Cancer Center
Stanford University
Wake Forest University Health Sciences
AstraZeneca
Merck Sharp & Dohme LLC
Fondazione del Piemonte per l'Oncologia
Mayo Clinic
Aminex Therapeutics, Inc.
Hoffmann-La Roche
Psyence Australia Pty Ltd
ViroMissile, Inc.
Hummingbird Bioscience
Dana-Farber Cancer Institute
Kaiser Permanente
Mayo Clinic
Washington University School of Medicine
University of Florida
Memorial Sloan Kettering Cancer Center
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
Essen Biotech
Essen Biotech
St. Jude Children's Research Hospital
Sapience Therapeutics
MacroGenics